Raltitrexed , ≥98% , 112887-68-0

Synonym(s):
L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl);ICI-D-1694;ZD-1694

CAS NO.：112887-68-0

Empirical Formula: C21H22N4O6S

Molecular Weight: 458.49

MDL number: MFCD00864168

EINECS: 652-997-2

PRODUCT Properties

• Melting point: 176-1800C
• Density: 1.49±0.1 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: H2O: ≥10mg/mL
• form: solid
• pka: 3.50±0.10(Predicted)
• color: off-white to light yellow
• InChIKey: IVTVGDXNLFLDRM-HNNXBMFYSA-N

Description and Uses

Tomudex was launched in Ireland, France, Luxembourg and the UK for advanced colorectal cancer and it was prepared in a convergent manner (6 steps) from diethyl L-glutamate and 6-bromomethyi-2-methyl-quinazolin4(3H)-one. Tomudex is a highly selective inhibitor of thymidylate synthase (TS), the key enzyme in the biochemical conversion of dUMP to dTMP. It enters the cell via the reduced folatefmethotrexate cell membrane carrier and is converted to the polyglutamate species by folylpolyglutamate synthase within 4h where it then binds to the folate substrate site of TS. Clinically, it had a 29% response rate in patients with advanced colorectal cancer. It is water soluble, can be administered as a single dose every three weeks and had no hepto- or nephrotoxicity.

Folate-based inhibitor of thymidylate synthase; rapidly and extensively metabolized to its more potent polyglutamate derivatives. Antineoplastic

Safety

• Symbol(GHS): GHS06,GHS08
• Symbol(GHS): GHS06,GHS08
• Signal word: Danger
• Signal word: Danger
• Hazard statements: H300-H360
• Hazard statements: H300-H360
• Precautionary statements: P201-P301+P310+P330
• Precautionary statements: P201-P301+P310+P330
• Hazard Codes: Xi,T
• Risk Statements: 36/38-25-61
• Safety Statements: 26-37/39-45-53
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 2
• HS Code: 2934.99.4700